Early studies defined a cut-off of at least two instable markers out of seven (MYCL1, D20S82, D20S85, L17835, D8S321, D9S242 and D19S394) to define EMAST, resulting in prevalence rates as high as 60% in colorectal cancer. This evidence concerns the gene MYCL and colorectal cancer.